Update on the heparin recall. Heparin is a blood thinner derived from pig intestines.
Survey about whether drug companies should hand out off-label drug studies to doctors.
Late yesterday, Baxter International ordered a full-scale recall on the blood thinner Heparin.
I don’t know how many times I’ve seen the commercial where a beaver is talking to Abe Lincoln at a bus stop about some guy in a suit not being able to sleep. Or Dr. Jarvik (or his double?) rowing in a beautiful lake while telling us how Lipitor is the greatest thing since the last few blockbuster statins.
I needed an antidote. Too many drug ads—smiling people glowing with the pleasure of their successful medical treatments. But of course, they are actors.
As a camp counselor for children with disabilities a couple years ago, I never stopped to consider that one of my bipolar campers may have been on eight different kinds of medication.
A newly released study indicates that Vytorin, an expensive new cholesterol drug, is no more effective than an older drug Zocor. Although the drug makers got these results in April 2006, they failed to release them to doctors and the public–meanwhile earning $5 billion in revenue from sales of this drug last year. Sadly, we’re not shocked.
The New England Journal of Medicine issued a report that said a third of FDA-registered studies on popular antidepressants went unpublished.
If you ignore the plethora of drug ads on TV, you might want to check your email.
If you are poor, uninsured, non-English speaking, or an ethnic or racial minority, you are less likely to receive free drug samples, according to a first of its kind study by Harvard researchers at the Cambridge Health Alliance.